Subjective and psychopathological response in patients under different antipsychotic treatments: Are there differences in real clinical practice?

Journal of Biological Regulators and Homeostatic Agents

Volumn 22, Issue 1, 2008, Pages 83-91

  Pollice, Rocco ^b   Tomassini, A ^b   Malavolta, M ^b   Di Giovambattista, E ^b   Verni, L ^b   Roncone, R ^b   Conti, C M ^a   Casacchia, M ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Atypical antipsychotic; Compliance; Psychopathological state; Subjective well being; Typical antipsychotic

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG RESPONSE; EMOTIONAL STABILITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; PATIENT COMPLIANCE; PHYSICAL PERFORMANCE; PSYCHIATRIC DEPARTMENT; SCHIZOPHRENIA; SCORING SYSTEM; SELF CONTROL; SOCIAL INTERACTION; STATISTICAL SIGNIFICANCE; WELLBEING;

ADULT; AGE OF ONSET; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PSYCHOTIC DISORDERS; SELF CONCEPT; SOCIAL BEHAVIOR;

AQUILA;

EID: 42549112195     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Amdt S, Andreasen NC, Flaum M et al. A longitudinal study of symptom dimension in schizophrenia: prediction and patterns of change. Arch Gen Psychiatry 1995; 52:352-360.
2. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60(10):5-14.
3. National Collaborating Centre for Mental Health. Schizofrenia. Linee Guida cliniche complete per gli interventi fondamentali nella Medicina di base e specialistica. Il Pensiero Scientifico Editore, Torino, 2004; p. 1.
4. Expert Consensus Guide-line Series Optimizing Pharmacologic Treatment of Psychotic Disorders. J Clin Psychiatry 2003; 64:1-97.
5. Buchanan RW, Breier A, Krikpatrick B et al. Positive and negative symptom response to clozapine in schizophrenic patients with and without deficit syndrome. A J Psychiatry 1998; 155:751-760.
6. Wirshing DA, Marshall BD Jr, Green MF et al. Risperidone in treatment-refractory schizophrenia. A J Psychiatry 1999; 156:1374-1379.
7. Conley RR, Tamminga CA, Bartko JJ et al. Olanzapine compared with chlorpromazine for treatment-resistant schizophrenia. Am J Psychiatry 1998; 155:914-920.
8. Arvanitis LA, Miller BG, for the Seroquel Trial 13 Study Group. Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry 1997; 42:233-246.
9. Peuskens J, for Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166:712-726.
10. Robinson DG, Lieberman JA, Sheitman B et al. Pilot study of atypical antipsychotic agents in first episode schizophrenia [abstract]. Schizophrenia Res 1997; 24: 196.
11. Ranger TM, Lieberman JA, Tohen M et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156:79-87.
12. Rosenhek R, Cramer J, Xu W et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England J Med 1997; 337:809-815.
13. Tran PV, Tollefson GD, Ranger TM et al. Olanzapine versus haloperidol in treatment of schizoaffective disorder. Br J Psychiatry 1999; 174:15-22.
14. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000; 61:638-642.
15. Tollefson GD, Ranger TM, Lu Y et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250-258.
16. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005; 66:40-8.
17. Corrigan PW, Lieberman RP, Engel JD. From non-compliance to collaboration in the treatment of schizophrenia. Hospital Community Psychiatry 1990; 41:1203-1211.
18. Putzhammer A, Perfhal M, Pfeiff L, Hajak G. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status. Pharmacopsychiatry 2005; 38:132-138.
19. Roncone R, Ventura J, Impallomeni M, Faloon IR, Morosini PL, Chiaravalle E, Casacchia M. Reliability of an Italian standardized and expanded Brief Psychiatric Rating Scale (BPRS 4.0) in raters with high vs low clinical experience. Acta Psychiatr Scand, 1999; 100:229-236.
20. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a reexamination comparing two measures. Psychol Med 1992; 22:347-352.
21. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life and other clinical variables. Int Clin Psychopharmacol 1995; 10(3): 133-138.
22. Naber D, Moritz S, Lambert M et al. Improvement of schizophrenic patients, subjective well-being under atypical antipsychotic drugs. Schizophrenia Res 2001; 50:79-88.
23. Norusis MJ. SPSS for Windows. User's Guide. Release 5.0. SPSS 1993, Chicago, IL.
24. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psycholog Med 1983; 13:177-183.
25. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin 1993; 19: 609-618.
26. Awad AG, Hogan TP. Drug therapy in schizophrenia: prediction of outcome. Schizophrenia Res 1988; 1: 222.
27. Hogan TP, Awad AG. Subjective response to neuroleptics in schizophrenia: a reexamination comparing two measures. Psycholog Med 19922; 2: 347-352.
28. Bellino S, Fulcheri M, Zizza M, Paradiso E, Conti CM, Doyle R, Bogetto F. Psychometric comparison of students in medicine and other faculties: social factors and psychologic symptoms J Biol Regul Homeostat Agents 2006; 20:73-78.
29. Speranza L, Grilli A, Patruno A, Franceschelli S, Felzani G, Pesce M, Vinciguerra I, De Lutiis MA, Felaco M. Plasmatic markers of muscular stress in isokinetic exercise. J Biol Regul Homeostat Agents 2006; 21:23-32.
30. Garcìa-Cabeza I., Gomez JC, Sacristan JA, Edgell E, Gonzales de Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO study). BioMed Central Psychiatry 2001; 1:7-15.
31. Mayerhofer M, Aichberger KJ, Florian S, Valent P. Recognition-sites for microbes and components of the immune system on human mast cells: relationship to CD antigens and implications for host defense. Int J Immunopathol Pharmacol 2007; 20:421-434.
32. Cinnella G, Vendemiale G, Dambrosio M, Serviddio G, Pugliese PL, Aspromonte G, Altomare E. Effect of Propofol, Sevoflurane and desflurane on systemic redox balance. Int J Immunopathol Pharmacol 2007; 20:585-594.
33. Browne S, Caravan J, Gervin M et al. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nervous Mental Dis 1998; 186:74-78.
34. Awad AG, Voruganti LN, Heslegrave RJ, Hogan TP. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol Supply 1996; 11:55-59.
35. Voruganti LN, Heslegrave RJ, Awad AG. Neuroleptic disphoria may be the missing link between schizophrenia and substance abuse. J Nervous Mental Dis 1997; 185:463-465.
36. Bocchietto E, Paolucci C, Breda D, Sabbioni E, Burastero SE. Human monocytoid THP-1 cell line versus monocyte-derived human immature dendritic cells as in vitro models for predicting the sensitising potential of chemicals. Int J Immunopathol Pharmacol 2007; 20:259-266.
37. Feliciani C, Ruocco E, Zampetti A, Toto P, Amerio Pa, Tulli A, Amerio P, Ruocco V. Tannic acid induces in vitro acantholysis of keratinocytes via IL-1α and TNF-α. Int J Immunopathol Pharmacol 2007; 20: 289-300.
38. D'Arcangelo C, Dinardo-Dimaio F, Stracci N, Spoto G, Malagnino VA, Caputi S. Pulp-dissolving ability of several endodontic irrigants: a spectrophotometric evaluation. Int J Immunopathol Pharmacol 2007; 20: 381-386.
39. Collins EJ, Hogan TP, Desai H. Measurement of therapeutic response in schizophrenia: a critical survey. Schizophren Res 1991; 5:249-253.
40. Sbarsi I, Falcone C, Boiocchi C, Campo I, Zorzetto M, De Silvestri A, Cuccia M. Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease. Int J Immunopathol Pharmacol 2007; 20:145-154.
41. Castellani ML, Bhattacharya K, Tagen M, Kempuraj D, Perrella A, De Lutiis M, Boucher W, Conti P, Theoharides TC. Anti-chemokine therapy for inflammatory diseases. Int J Immunopathol Pharmacol 2007; 20:447-454.
42. Hellewell J. Patient's subjective experiences of antipsychotics. Clin Relevance 2002; 16:457-471.
43. Tempier R, Pawliuk N. Influence of novel and conventional antipsychotic medication on subjective quality of life. J Psychiatric Neurosci 2001; 26:131-136.
44. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002; 162:3-10.
45. Voruganti LN, Awad AG. Personal evaluation of transitions in treatment: a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophrenia Res 2002; 56:37-46.
46. Ritsner M, Perelroyzen G, Ilan H, Gibel A. Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice. A naturalistic comparative study. J Clin Psychopharmacol 2004; 3: 245-253.
47. Gerlach J, Larsen EB. Subjective experience and mental side effects of antypsychotic treatment. Acta Psychiatrica Scand 1999; 99:113-117.
48. Fitzgerald PB, Williams CL, Corteling N et al. Subject and observer rated quality of life in schizophrenia. Acta Psychiatrica Scand 2001; 103:387-392.
49. D'Alimonte I, Ciccarelli R, Di Iorio P, Nargi E, Buccella S, Giuliani P, Rathbone MP, Jiang S, Caciagli F, Ballerini P. Activation of P2X7 receptors stimulates the expression of P2Y2 receptor mRNA in astrocytes cultured from rat brain. Int J Immunopathol Pharmacol 2007; 20:301-315.
50. Rosati E, Mencarelli S, Magini A, Sabatini R, Tassi C, Orlacchio A, Coaccioli S, Frenguelli A, Marconi P, Emiliani C. Enhancement of lysosomal glycohydrolase activity in human primary B lymphocytes during spontaneous apoptosis. Int J Immunopathol Pharmacol 2007; 20:279-288.
51. Ingber A, Cohen Y, Krimsky M, Yedgar S. A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo controlled pilot study. Int J Immunopathol Pharmacol 2007; 20:191-195.
52. Haan de L, Lavalaye J, Linszen DH et al. Subjective experience and striatal dopamine d2 receptor occupancy in patients with schizophrenia stabilized on olanzapine or risperidone. Am J Psychiatry 2000; 157:1019-1020.
53. Naber D, Walther A, Kircher T et al. Subjective effects of neuroleptics predict compliance. In: Gaebel W, Awad AJ. Prediction of neuroleptic treatment outcome in schizophrenia concepts and methods. Ed. Springer, Berlin Heidelberg New York, 1994, p. 1.
54. Capodiferro S, Scully C, Ficarra G, de Frenza G, Grassi R, Maiorano E, Favia G, Mastrangelo F, Tetè S. Orofacial granulomatosis: report of two cases with gingival onset. Eur J Inflamm 2007; 5:51.
55. Ahangari G, Chavoshzadeh Z, Lari Z, Ramyar A, Farhoudi A. Novel mutation detection of an inflammatory molecule Elastase II gene encoding neutrophil Elastase in Kostmann syndrome. Eur J Inflamm 2007; 5:65-72.
56. Deviri E, Glenville BE. Inflammatory response in infective endocarditis. Eur J Inflamm 2007; 5: 57-63.
57. American Psychiatric Association. Practice guideline for the Treatment of Patients with Schizophrenia. American Psychiatric Association, 2004, p. 1.